Emily Pettitt

Emily Pettitt

Research
Emily Pettitt

Emily Pettitt

Research
Amy Conrad

Amy Conrad

Investor Relations
Amy Conrad

Amy Conrad

Investor Relations
Alena Zalutskaya

Alena Zalutskaya

Clinical
Alena Zalutskaya

Alena Zalutskaya

Clinical
Sarah Honig

Sarah Honig

VP, Corporate Development & Strategy
Bio
Sarah Honig

Sarah Honig

VP, Corporate Development & Strategy

Sarah Honig joined TYRA in July of 2022 as our Vice President, Corporate Development and Strategy. Prior to joining TYRA, Sarah was the Chief of Staff at Allogene Therapeutics, where she drove corporate and portfolio strategy, governance, and operations since the inception of the company. Previously, Sarah spent time leading transactions as part of Amgen’s Business Development Team and co-founded the New Ventures group at UCLA’s Office of Intellectual Property.  She began her career consulting for biotechnology companies on corporate development, portfolio and commercial strategy at Leerink Swann. Sarah holds an A.B. from Harvard College and an M.B.A. from Harvard Business School.

Marazban Sarkari

Marazban Sarkari

Development
Marazban Sarkari

Marazban Sarkari

Development
Fernando Blanco

Fernando Blanco

Clinical
Fernando Blanco

Fernando Blanco

Clinical
Fernando de Miguel

Fernando de Miguel

RESEARCH
Fernando de Miguel

Fernando de Miguel

RESEARCH
Samhita Iyer

Samhita Iyer

Research
Samhita Iyer

Samhita Iyer

Research
Julia Rueb

Julia Rueb

VP, FINANCE
Julia Rueb

Julia Rueb

VP, FINANCE
Robert L. Hudkins

Robert L. Hudkins

Chief Technology Officer
Bio
Robert L. Hudkins

Robert L. Hudkins

Chief Technology Officer

Robert Hudkins serves as our Chief Technology Officer having joined Tyra in January 2020. He brings over 30 years of drug discovery experience including all aspects of drug design and computational chemistry. Prior to joining Tyra, Bob spent the majority of his career with Cephalon, Inc., and later with Teva Pharmaceuticals where he was a Distinguished Scientist and Senior Research Fellow / Senior Research Director in Medicinal Chemistry responsible for the advancement of numerous clinical candidates in oncology and neuroscience. He has co-authored over 100 publications, and was co-inventor on over 123 published US patents. Bob serves as a Journal Editorial Advisory Board Member for multiple medicinal chemistry journals. He holds a B.S. from Barton College, a M.S. in Organic Chemistry from Old Dominion University, and a Ph.D. in Medicinal Chemistry from Virginia Commonwealth University.

Susan Moran

Susan Moran

Board member
Bio
Susan Moran

Susan Moran

Board member

Dr. Moran has over 20 years of industry and academic experience, successfully leading clinical trials from Phase 1 to Phase 3, as well as overseeing NDA and MAA submissions for various investigational products, including the successful approval of Nerlynx. Dr. Moran most recently served as the Chief Medical Officer of RayzeBio, a clinical-stage radiopharmaceutical therapeutics company (acquired by Bristol Meyers Squibb in February 2024). Prior to RayzeBio, she was Chief Medical Officer of QED Therapeutics, an affiliate of BridgeBio Pharma, where she oversaw the clinical development of infigratinib, leading to approval of Truseltiq. Before QED, Dr. Moran was VP and Head of Clinical Development at Puma Biotechnology and previously held senior positions at Takeda (previously Millennium) and Sanofi (former Genzyme). Dr. Moran has played roles in the development, registration, and post-marketing support of products for a number of solid tumors, including bile duct, urothelial, and liver cancer, among others, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board-certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine. Dr. Moran currently serves on the board of directors of BioAtla, Inc., a clinical-stage biotechnology company.

Christine Yang

Christine Yang

Clinical
Christine Yang

Christine Yang

Clinical
Cory Scott

Cory Scott

Finance
Cory Scott

Cory Scott

Finance
Curt Dvorak

Curt Dvorak

Chemistry
Curt Dvorak

Curt Dvorak

Chemistry
Corbin Occhino

Corbin Occhino

Research
Corbin Occhino

Corbin Occhino

Research
Gary Price

Gary Price

VP, Quality
Gary Price

Gary Price

VP, Quality
Rehan Verjee

Rehan Verjee

Board Member
Bio
Rehan Verjee

Rehan Verjee

Board Member

Rehan Verjee has served as a member of our Board since June 2021. Mr. Verjee is currently the founding CEO of Precede Biosciences, a venture-backed, liquid-biopsy diagnostic company. Prior to founding Precede Biosciences, Mr. Verjee was a member of the Healthcare Executive Committee of Merck KGaA from October 2015 to March 2021. During this time, Mr. Verjee served as the President of EMD Serono and as the Chief Marketing and Strategy officer for the Healthcare business of Merck KGaA. As the President of EMD Serono, Mr. Verjee led a significant enterprise through a period of transformation and growth that included the FDA approval and launch of four new medicines. As the Chief Marketing and Strategy Officer of Merck’s Healthcare business, Mr. Verjee was accountable for product and portfolio strategy across all specialty medicine therapeutic areas (oncology, neurology, immunology and infertility), a role that included co-chairing the R&D development committee (responsible for all R&D decisions from Phase 1 to approval), leading global business development, chairing significant global R&D alliances, and having responsibility for the launches of new medicines across the major markets including the USA, the EU, China and Japan. Mr. Verjee is currently a member of the board of directors of the Massachusetts Biotechnology Council and of Precede Biosciences. Mr. Verjee holds a Master's Degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.

Robert More

Robert More

Board Member
Bio
Robert More

Robert More

Board Member

Robert More is a Managing Director at Alta Partners, a healthcare focused venture capital firm. Bob currently manages investments in and serves on the board of Affinivax, eGenesis, Qihan Biopharmaceuticals, and Vir Biotechnology (NASDAQ:VIR). He was a founding board member of the Kauffman Fellows Program and is on the board of BIO (Biotechnology Innovation Organization). Before joining Alta, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.

Ruby Haro

Ruby Haro

FINANCE
Ruby Haro

Ruby Haro

FINANCE
Tristen Asmann

Tristen Asmann

Finance
Tristen Asmann

Tristen Asmann

Finance
Sherry Owens

Sherry Owens

Clinical
Sherry Owens

Sherry Owens

Clinical
Maggie Wong

Maggie Wong

FINANCE
Maggie Wong

Maggie Wong

FINANCE
Alan Fuhrman

Alan Fuhrman

Chief Financial Officer
Bio
Alan Fuhrman

Alan Fuhrman

Chief Financial Officer

Mr. Fuhrman is a veteran leader and board member in the biotechnology industry, with a proven track record of guiding companies through key periods of growth including late-stage clinical development, and strategic transactions with pharmaceutical partners, including mergers and acquisitions. Prior to joining TYRA, Mr. Fuhrman served as interim President, CEO and board member of Checkmate Pharmaceuticals, Inc. from October 2021 through February of 2022 and remained on the board of directors until its acquisition by Regeneron in May 2022. Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020. Before joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company, that merged with Synlogic in August 2017. Mr. Fuhrman also served on the board of directors and as Chair of the Audit Committee for Loxo Oncology from January 2015 until its sale to Eli Lilly in February 2019. Mr. Fuhrman previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in January 2015. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. He received a B.S. in both Business Administration and Agricultural Economics from Montana State University. Currently, he is a member of the board of directors of both SpringWorks Therapeutics and Esperion Therapeutics.

Nina Kjellson

Nina Kjellson

Board Member
Bio
Nina Kjellson

Nina Kjellson

Board Member

Nina Kjellson is a General Partner at Canaan. Nina invests in biopharma and digital health companies that serve unmet therapeutic and access needs. As a leader of Canaan’s Women of Venture program, Nina is a vocal advocate for women entrepreneurs and investors. She serves as a mentor to Blueprint Health and Springboard Life Sciences and on the boards of Essential Access Health, the California Leadership Council for The Nature Conservancy and the Oliver Wyman Health Innovation Center. Nina is also a 2018 Aspen Institute Health Innovators Fellow. Previously, Nina was a General Partner at Interwest Partners. She holds a B.A. in human biology from Stanford University.

Tim Burn

Tim Burn

Clinical
Tim Burn

Tim Burn

Clinical
Melissa Gonzalez

Melissa Gonzalez

Finance
Melissa Gonzalez

Melissa Gonzalez

Finance
Tonya Blizzard

Tonya Blizzard

FINANCE
Tonya Blizzard

Tonya Blizzard

FINANCE
Katherine Hogg Call

Katherine Hogg Call

Clinical
Katherine Hogg Call

Katherine Hogg Call

Clinical
Mohamed Ahmed

Mohamed Ahmed

Research
Mohamed Ahmed

Mohamed Ahmed

Research
Kirk Nelson

Kirk Nelson

Research
Kirk Nelson

Kirk Nelson

Research
Isaac Hoffman

Isaac Hoffman

Research
Isaac Hoffman

Isaac Hoffman

Research
Sydney Borden

Sydney Borden

Clinical
Sydney Borden

Sydney Borden

Clinical
Jacqueline Starrett

Jacqueline Starrett

Research
Jacqueline Starrett

Jacqueline Starrett

Research
George Melko

George Melko

VP, Regulatory Affairs
George Melko

George Melko

VP, Regulatory Affairs
Rafael Cassata

Rafael Cassata

Regulatory affairs
Rafael Cassata

Rafael Cassata

Regulatory affairs
Phoebe Clowser

Phoebe Clowser

Research
Phoebe Clowser

Phoebe Clowser

Research
Liz Pagano

Liz Pagano

SVP, HR
Liz Pagano

Liz Pagano

SVP, HR
Doug Warner, M.D.

Doug Warner, M.D.

Chief Medical Officer
Bio
Doug Warner, M.D.

Doug Warner, M.D.

Chief Medical Officer

Doug Warner was appointed Chief Medical Officer of TYRA in September 2024. Prior to joining TYRA, Dr. Warner held roles of increasing responsibility over 18 years at Amgen where he oversaw clinical development for programs across oncology and bone diseases. This included being an Executive Director and Group Product Area Lead, where Dr. Warner led a team responsible for the development of a portfolio of medicines ranging from those in Phase 1 to those with approved indications, including Vectibix®, XGEVA®, and Prolia®. Most recently, Dr. Warner was Chief Medical Officer for eFFECTOR Therapeutics where he was responsible for overseeing eFFECTOR’s clinical pipeline, including its KICKSTART Phase 2b trial of tomivosertib in non-small cell lung cancer, and its Phase 1/2 study of zotatifin in solid tumors. Dr. Warner is co-author of numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology, and The Journal of Clinical Oncology. He received his B.A. from the University of Pennsylvania, his M.D. from the Duke University School of Medicine, and his M.B.A. from the UCLA Anderson School of Management.

Todd Harris

Todd Harris

Chief Executive Officer
Bio
Todd Harris

Todd Harris

Chief Executive Officer

Todd Harris is Chief Executive Officer of Tyra which he co-founded in August 2018. Prior to co-founding Tyra, Todd co-founded Sienna Biopharmaceuticals, Inc. (SNNA) a clinical-stage biopharmaceutical company where he was Chief Executive Officer and a member of the board of directors. Todd started his career as a consultant at McKinsey & Company in the Health Care Practice Division. Todd currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical company focused on the second arm, innate immune system. Todd holds a B.S. in Electrical Engineering from Brigham Young, a M.S. in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology.

Melissandre Pache

Melissandre Pache

Research
Melissandre Pache

Melissandre Pache

Research
Jake Simson

Jake Simson

Board Member
Bio
Jake Simson

Jake Simson

Board Member

Jake Simson, Ph.D. is a Partner at RA Capital Management, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies developing drugs, medical devices, and diagnostics. Dr. Simson works on both public and private investments and serves as a Board Director for Xenikos, B.V, Janux, AavantiBio, and DiCE Molecules. He holds a B.S. in materials science and engineering from MIT and a Ph.D. in biomedical engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.

Scott Drew

Scott Drew

IT
Scott Drew

Scott Drew

IT
Ronald V. Swanson

Ronald V. Swanson

Chief Scientific Officer
Bio
Ronald V. Swanson

Ronald V. Swanson

Chief Scientific Officer

Ronald Swanson serves as our Chief Scientific Officer having joined Tyra in August 2019 and brings over 26 years of biotech and pharma experience. Prior to joining Tyra, Ron served as Senior Director, Biologics at Johnson & Johnson, Inc. where he focused on new technologies and engineering of antibodies, peptides and protein therapeutics. Prior to J&J, he was co-founder and Chief Scientific Officer at ActiveSight, the contract crystallography arm of Rigaku Americas Corporation. Ron was also previously at Syrrx and Diversa and was a post-doc at Caltech. Ron holds a B.A. in Biochemistry and Cell Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of California, Berkeley.

Alexandra Balcer

Alexandra Balcer

Clinical
Alexandra Balcer

Alexandra Balcer

Clinical
Kelleen Chea

Kelleen Chea

Office Manager
Kelleen Chea

Kelleen Chea

Office Manager
Marc Rideout

Marc Rideout

Research
Marc Rideout

Marc Rideout

Research
Melissa Ye

Melissa Ye

Clinical
Melissa Ye

Melissa Ye

Clinical
Christine Lihou

Christine Lihou

Clinical
Christine Lihou

Christine Lihou

Clinical
Ali Fawaz

Ali Fawaz

LEGAL
Bio
Ali Fawaz

Ali Fawaz

LEGAL

Ali Fawaz joined TYRA in May 2022 as our General Counsel and Secretary. Prior to joining TYRA, Ali served as Vice President and Deputy General Counsel at Sampled (formerly Infinity BiologiX LLC), where he was a member of the senior management team focused on leading the legal affairs and corporate strategy for the company.  Previously, Ali worked at Celgene Corporation where he served as the lead legal negotiator on all employee related matters in connection with the $74B acquisition of Celgene by Bristol Myers Squibb.  Prior to that, Ali was a Partner at Proskauer Rose LLP in New York City, and before that, was a Senior Associate at Latham & Watkins LLP in San Diego and Washington, DC.  Ali holds a B.A. degree in Business Administration (Finance and General Management) from Portland State University and a J.D. from the University of Michigan Law School

S. Michael Rothenberg

S. Michael Rothenberg

Board Member
Bio
S. Michael Rothenberg

S. Michael Rothenberg

Board Member

Dr. Rothenberg is a trained oncologist who brings two decades of clinical care and drug development experience across multiple therapeutic modalities to the TYRA board spanning target identification through approval. Dr. Rothenberg currently serves as the Chief Medical Officer of insitro, a machine learning-powered drug discovery and development company, where he leads all aspects of clinical development. Prior to insitro, he was vice president of early oncology development and clinical research at Pfizer, where he oversaw Pfizer's oncology and hematology early clinical development portfolio, advancing more than 20 first-in-patient clinical trials, including supervising elranatamab (Elrexfio™, a bispecific antibody) through the first-in-human trial to human proof-of-concept. Prior to Pfizer, he was Vice President of Research and Development at Loxo Oncology, where he led early clinical development for novel, targeted anticancer therapies, including the approved RET inhibitor RETEVMO® (selpercatinib). He previously served as a medical oncologist and researcher focused on targeted therapeutics at Massachusetts General Hospital. Dr. Rothenberg received his B.A. from Yale University and his M.D. and Ph.D. from Stanford University.

Daniel Bensen

Daniel Bensen

Chief Operating Officer
Bio
Daniel Bensen

Daniel Bensen

Chief Operating Officer

Daniel Bensen is Chief Operating Officer of Tyra which he co-founded in August 2018. Prior to co-founding Tyra, Dan served as Head of Immunology and Protein Chemistry at Cidara Therapeutics, Inc. where he led cross functional research groups pioneering a novel immunotherapeutic platform resulting in two candidates. Before Cidara, Dan served as Principal Scientist, Protein Chemistry and Structural Biology at Trius Therapeutics, Inc where he oversaw efforts to generate and advance a novel class of dual-targeting broad spectrum antibacterial agents until its acquisition by Cubist Pharmaceuticals. Before Trius, Dan held positions of increasing responsibility in structural biology and protein chemistry at ActiveSight and Diversa. Dan holds a B.A. in Biology from Point Loma Nazarene University and an M.B.A. from the University of Southern California, Marshall School of Business.

Melissa Neal

Melissa Neal

Research
Melissa Neal

Melissa Neal

Research
Ed Slezinger

Ed Slezinger

Ed Slezinger

Ed Slezinger

Gilla Kaplan

Gilla Kaplan

Board Member
Bio
Gilla Kaplan

Gilla Kaplan

Board Member

Gilla Kaplan, Ph.D. is the Chief Executive Officer of Gilrose Therapeutics and a Senior Advisor of Medicine Development for Global Health. Before Gilrose, Dr. Kaplan was Senior Advisor at the Bill and Melinda Gates Medical Research Institute (Gates MRI) and the Director of the Global Health Program, Tuberculosis of the Bill and Melinda Gates foundation (BMGF). She has spent her career as an academic research scientist leading a laboratory in investigations focusing on human disease, exploring novel experimental medicine approaches that modulate the immune response for disease control. She was a recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan currently serves on the board of directors of Cerecor. She previously served on the board of directors at Celgene for 20 years. Dr. Kaplan received a Bachelor of Science degree from Hebrew University, Jerusalem, Israel and a Master of Science and Ph.D. in Cellular Immunology from University of Tromso, Norway.

Michael Bober

Michael Bober

VP, Clinical Development & Medical Affairs
Michael Bober

Michael Bober

VP, Clinical Development & Medical Affairs
Piyush Patel

Piyush Patel

Chief Development Officer
Bio
Piyush Patel

Piyush Patel

Chief Development Officer

Piyush Patel has served as our Chief Development Officer since January 2021 and brings over 29 years of drug development experience including all aspects of nonclinical and product development of small molecules. Prior to joining Tyra, Piyush was the Chief Scientific Officer at CinRx Pharma, LLC where he oversaw the development of multiple small molecule programs from drug candidate selection to IND submission. Prior to CinRx he was a Senior Director at Teva Pharmaceutical Industries Ltd responsible for global formulation development, clinical manufacture, process development/Pharmaceutical Operations and CMC documentation groups. He has authored several scientific publications and is a co-inventor on multiple patents. Piyush holds a Bachelor of Pharmacy from the Maharaja Sayajirao University of Baroda, and a M.S. and Ph.D. in Pharmaceutical Sciences from Temple University.

Molly Pace

Molly Pace

Development
Molly Pace

Molly Pace

Development
Melissa McCracken

Melissa McCracken

Board Member
Bio
Melissa McCracken

Melissa McCracken

Board Member

Melissa McCracken, Ph.D., is a Principal at Nextech Invest Ltd., where she manages investments in companies pursuing emerging cancer therapies. Dr. McCracken currently serves as a board observer of IconOvir, and previously served as a board member of ImaginAb and a board observer of Silverback Therapeutics. Prior to Nextech, she was a senior associate at Third Rock Ventures. Prior to that, Dr. McCracken completed multiple internships in research and development at Amgen (NASDAQ: AMGN). She holds a B.S. in biochemistry and molecular biology from University of California, Davis, and a Ph.D. in molecular and medical pharmacology from University of California, Los Angeles, where her research focused on engineered immunity for cancer. She also completed a postdoctoral fellowship at Stanford University where her research focused on immuno-oncology.

Michelle Norton

Michelle Norton

Clinical
Michelle Norton

Michelle Norton

Clinical
Eric Allen

Eric Allen

Research
Eric Allen

Eric Allen

Research

JOIN THE TEAM

Our open and collaborative culture gives each of us the support and responsibility to create novel oncology therapies that overcome acquired drug resistance.